Indication | Therapy | TMB cut-off | Panel | Variant types included | Ref. |
Melanoma | Ipilimumab | >2.5/ Mb* | WES | Non-synonymous | 31 |
NSCLC | Pembrolizumab | >4.5/ Mb* | WES | Non-synonymous | 32 |
NSCLC | Nivolumab+Ipilimumab | >4.0/ Mb* | WES | Non-synonymous | 33 |
NSCLC | Nivolumab+Ipilimumab | >10/ Mb | FM | All coding | 34–36 |
NSCLC | Anti-PD-1 or -PD-L1 | Descriptive | MSK | Non-synonymous | 37 |
Melanoma | Ipilimumab | Descriptive | WES | Non-synonymous | 38 |
Urothelial | Atezolizumab | Descriptive | FM | All coding | 39 |
NSCLC | Nivolumab | >6.2/ Mb* | WES | Non-synonymous | 40 |
Multiple | Anti- CTLA4/PD-1/PD-L1 | >20/ Mb | FM | All coding | 13 |
Multiple | Anti- CTLA4/PD-1/PD-L1 | Tumor dependent | MSK | Non-synonymous | 41 |
*39.4 Mb/exome.
FM, foundation medicine foundation one CDx assay; MSK, memorial sloan kettering IMPACT assay; NSCLC, non-small-cell lung cancer; TMB, tumor mutation burden; WES, whole-exome sequencing.